173 related articles for article (PubMed ID: 7998111)
61. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
62. Coactivation with anti-CD28 monoclonal antibody enhances anti-CD3 monoclonal antibody-induced proliferation and IL-2 synthesis in T cells from autologous bone marrow transplant recipients.
Lum LG; Joshi ID; Galoforo SC; Abella E; Karanes C; Ratanatharathorn V; Schultz KR; Uberti JP; Sensenbrenner LL; Ledbetter JA
Bone Marrow Transplant; 1993 Dec; 12(6):565-71. PubMed ID: 8136739
[TBL] [Abstract][Full Text] [Related]
63. Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells.
Ochi H; Abraham M; Ishikawa H; Frenkel D; Yang K; Basso AS; Wu H; Chen ML; Gandhi R; Miller A; Maron R; Weiner HL
Nat Med; 2006 Jun; 12(6):627-35. PubMed ID: 16715091
[TBL] [Abstract][Full Text] [Related]
64. T-splenocytes from non-obese diabetic mice binding to xenogeneic pancreatic beta-cells in vitro. Implication of the alpha/beta T-cell receptor and of major histocompatibility complex class II molecules from target cells.
Martignat L; Feve B; Ouary M; Pogu S; Charbonnel B; Saï P
J Autoimmun; 1993 Dec; 6(6):753-69. PubMed ID: 8155255
[TBL] [Abstract][Full Text] [Related]
65. Cytokine-release syndrome: general risk-factor modification--preparation of high-risk patients for use of OKT3.
Radhakrishnan J; Cohen DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):60-2. PubMed ID: 8465429
[No Abstract] [Full Text] [Related]
66. [Clinical application of monoclonal antibodies].
Yata J
Ryumachi; 1984 Aug; 24(4):288-94. PubMed ID: 6393366
[No Abstract] [Full Text] [Related]
67. In vivo induction of IL-10 by anti-CD3 monoclonal antibody in mice.
Velu T; Durez P; Van Mechelen M; Gérard C; Abramowicz D; Moser M; Leo O; Goldman M
Transplant Proc; 1993 Feb; 25(1 Pt 1):568-9. PubMed ID: 8438417
[No Abstract] [Full Text] [Related]
68. Therapeutic strategies using monoclonal antibodies in autoimmune disease.
Pankewycz O; Strom TB; Kelley VE
Curr Opin Immunol; 1989 Apr; 1(4):757-63. PubMed ID: 2508704
[No Abstract] [Full Text] [Related]
69. [Monoclonal antibody therapy].
Schäffner G; Kabelitz D
Dtsch Med Wochenschr; 2001 Jul; 126(30):851-6. PubMed ID: 11512284
[No Abstract] [Full Text] [Related]
70. [Monoclonal antibodies and differentiation antigen groups: study methods and their applications to diagnostic use].
Sampalo Lainz A; López Gómez M
Med Clin (Barc); 1992 May; 99(1):30-6. PubMed ID: 1602897
[No Abstract] [Full Text] [Related]
71. Treatment of Guillain-Barré syndrome with anti-T cell monoclonal antibodies.
Feasby TE
J Neurol Neurosurg Psychiatry; 1991 Jan; 54(1):51-4. PubMed ID: 1901348
[TBL] [Abstract][Full Text] [Related]
72. IL-2 receptors in adult T-cell leukemia: a target for immunotherapy.
Waldmann TA; Kozak RW; Tsudo M; Oh-ishi T; Bongiovanni KF; Goldman CK
Haematol Blood Transfus; 1987; 31():110-5. PubMed ID: 3127278
[No Abstract] [Full Text] [Related]
73. Anti-CD3 antibody for autoimmune disease, a cautionary note.
Hirsch R; Gress RE; Bluestone JA
Lancet; 1989 Jun; 1(8651):1390. PubMed ID: 2567402
[No Abstract] [Full Text] [Related]
74. Lessons for transplant immunosuppression from the usage of cyclosporine in autoimmune diseases.
Bach JF
Transplant Proc; 1994 Oct; 26(5):3077-81. PubMed ID: 7940966
[No Abstract] [Full Text] [Related]
75. Neurotoxicity after treatment with muromonab-CD3.
Richards JM; Vogelzang NJ; Bluestone JA
N Engl J Med; 1990 Aug; 323(7):487-8. PubMed ID: 2115619
[No Abstract] [Full Text] [Related]
76. Use of monoclonal antibodies in vivo as a therapeutic strategy for alloimmune or autoimmune reactivity: the Besançon experience.
Herve P; Racadot E; Wendling D; Rumbach L; Tiberghien P; Cahn JY; Flesch M; Wijdenes J
Immunol Rev; 1992 Oct; 129():31-55. PubMed ID: 1464420
[No Abstract] [Full Text] [Related]
77. Aseptic meningitis and muromonab-CD3 therapy.
Drees C; Haley CJ
DICP; 1991 Feb; 25(2):138-9. PubMed ID: 1905440
[No Abstract] [Full Text] [Related]
78. Treatment of autoimmune diseases with monoclonal antibodies.
Wofsy D
Prog Allergy; 1988; 45():106-20. PubMed ID: 3064092
[No Abstract] [Full Text] [Related]
79. From antilymphocyte serum to therapeutic monoclonal antibodies: first experiences with a chimeric CD4 antibody in the treatment of autoimmune disease.
Riethmüller G; Rieber EP; Kiefersauer S; Prinz J; van der Lubbe P; Meiser B; Breedveld F; Eisenburg J; Krüger K; Deusch K
Immunol Rev; 1992 Oct; 129():81-104. PubMed ID: 1464423
[No Abstract] [Full Text] [Related]
80. Clinical and Basic Science Perspectives on the Use of OKT3. International symposium proceedings. Portland, Oregon, July 23-24, 1992.
Transplant Proc; 1993 Apr; 25(2 Suppl 1):1-93. PubMed ID: 8096662
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
